BioCentury
ARTICLE | Clinical News

FDA approves Merck's doravirine HIV therapies

September 7, 2018 7:35 PM UTC

Merck & Co. Inc. (NYSE:MRK) said FDA approved two doravirine-based therapies to treat HIV infection ahead of their Oct. 23 PDUFA date: once-daily Pifeltro doravirine for use in combination with antiretrovirals; and once-daily Delstrigo, a fixed-dose combination tablet of doravirine with lamivudine and tenofovir. Both therapies are indicated to treat HIV-1 infection in adults with no prior antiretroviral use.

Doravirine is a non-nucleoside HIV reverse transcriptase inhibitor (NNRTI). Lamivudine is a nucleoside reverse transcriptase inhibitor, and tenofovir is a nucleotide reverse transcriptase inhibitor...

BCIQ Company Profiles

Merck & Co. Inc.